Edition:
India

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

6,049.00GBp
5:40pm IST
Change (% chg)

111.00 (+1.87%)
Prev Close
5,938.00
Open
5,991.00
Day's High
6,064.00
Day's Low
5,982.00
Volume
859,429
Avg. Vol
2,225,476
52-wk High
6,540.00
52-wk Low
5,110.00

Select another date:

Wed, May 8 2019

Photo

AstraZeneca-Daiichi breast cancer treatment shows promise in latest study

An experimental breast cancer drug being developed by British drugmaker AstraZeneca and Japan's Daiichi Sankyo's met its main goal in a mid-stage study, bolstering their position in a highly competitive oncology market.

UPDATE 2-AstraZeneca-Daiichi breast cancer treatment shows promise in latest study

* Plan to seek FDA approval in second half of year (Adds details on regulatory submission, analyst comment on potential sales)

AstraZeneca ties up with France's Transgene to develop viral immunotherapies

British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.

AstraZeneca ties up with France's Transgene to develop viral immunotherapies

May 2 British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.

Newer drugs fuel AstraZeneca quarterly sales beat

AstraZeneca Plc beat first-quarter sales and earnings expectations on Friday as the British drugmaker benefited from a push into cancer drugs and emerging markets including China.

UPDATE 3-Newer drugs fuel AstraZeneca quarterly sales beat

* Current China growth rate not sustainable, still bullish (Adds executive comment, updates shares)

AstraZeneca first-quarter product sales beat estimates

April 26 British drugmaker AstraZeneca Plc's first-quarter product sales beat analysts' expectations on Friday, benefiting from higher demand for its cancer medicines.

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca Plc will pay up to $6.9 billion to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche.

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca Plc will pay up to $6.9 billion to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche.

Breakingviews - AstraZeneca takes precision approach to cancer M&A

LONDON (Reuters Breakingviews) - AstraZeneca is taking a precision approach in the race to treat cancer. The UK drugmaker on Thursday evening said it will pay up to $6.9 billion to work with Daiichi Sankyo on a treatment for breast cancer. Compared to the risk of an acquisition, it’s a relatively painless way of expanding in a hot area.

Select another date: